Economics • Practice • Informatics

Topic

Drug Development

Karolinska Institutet, Astra extend PET research alliance

Partnerships & Alliances | Monday, January 30
Karolinska Institutet in Stockholm and AstraZeneca have formed a three-year collaborative research agreement that will apply molecular imaging technologies to generate new diagnostic imaging tools.
 

FDA webinar: Single reports of adverse events can save lives

Regulatory News | Thursday, October 20
The FDA’s MedWatch program, established in 1993, allows physicians, nurses or patients to report an adverse event associated with an approved device or drug. Not only does the program evaluate and generate information based on the reports, but it also makes that information available to providers, manufacturers and the public, explained Brenda J. Rose, pharmaceutical director, Office of Special Health Issues, FDA, during an Oct. 20 FDA webinar.
 

Study: PET confirms efficacy of estrogen-blocking drugs

Clinical Studies | Sunday, August 21
18F-fluoroestradiol (FES) PET can assess the in vivo pharmacodynamics of estrogen receptor (ER)-targeted agents and may give insight into the activity of established therapeutic agents, according to a study in the August issue of Clinical Cancer Research.
 

U of Oklahoma taps ABT for FDG production

Contracts & Installations | Sunday, June 19
The University of Oklahoma in Norman, Okla., has completed installation of ABT Molecular Imaging's Biomarker Generator at the College of Pharmacy, enabling researchers at the university to have local access to PET radioisotopes.